Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.20
+0.16 (1.23%)
At close: Apr 28, 2026, 4:00 PM EDT
13.04
-0.16 (-1.21%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for Intellia Therapeutics stock have an average target of 20.02, with a low estimate of 5.00 and a high estimate of 58. The average target predicts an increase of 51.67% from the current stock price of 13.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Intellia Therapeutics stock from 23 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 8 | 8 |
| Buy | 4 | 4 | 2 | 2 | 4 | 4 |
| Hold | 10 | 10 | 8 | 8 | 7 | 9 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Total | 22 | 22 | 18 | 18 | 20 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $48 → $58 | Strong Buy | Maintains | $48 → $58 | +339.39% | Apr 28, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $8 → $9 | Strong Sell | Maintains | $8 → $9 | -31.82% | Apr 28, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $11 → $15 | Hold | Maintains | $11 → $15 | +13.64% | Apr 28, 2026 |
| Citizens | Citizens | Buy Maintains $28 → $30 | Buy | Maintains | $28 → $30 | +127.27% | Apr 28, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $27 → $30 | Strong Buy | Maintains | $27 → $30 | +127.27% | Apr 27, 2026 |
Financial Forecast
Revenue This Year
64.15M
from 67.67M
Decreased by -5.20%
Revenue Next Year
104.41M
from 64.15M
Increased by 62.75%
EPS This Year
-3.68
from -3.81
EPS Next Year
-3.13
from -3.68
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 105.0M | 202.7M | ||||||
| Avg | 64.2M | 104.4M | ||||||
| Low | 32.3M | 30.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 55.2% | 216.0% | ||||||
| Avg | -5.2% | 62.8% | ||||||
| Low | -52.2% | -52.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.04 | -1.76 | ||||||
| Avg | -3.68 | -3.13 | ||||||
| Low | -4.71 | -4.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.